Your shopping cart is currently empty

WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 1-2 weeks | 1-2 weeks | |
| 50 mg | $1,980 | 1-2 weeks | 1-2 weeks | |
| 100 mg | $2,500 | 1-2 weeks | 1-2 weeks |
| Description | WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor. |
| Targets&IC50 | EGFR:4 μM, RET:5 nM, KDR:66 nM |
| In vivo | WHI-P180 acts as an effective inhibitor of IgE-mediated mast cell responses. In CD-1 (BALB/c) mice, its elimination half-life is below 10 minutes across intravenous (i.v.), intraperitoneal (i.p.), and oral (p.o.) administrations. Systemic clearance rates for WHI-P180 are recorded at 6742 mL/h/kg in CD-1 mice and 8188 mL/h/kg in BALB/c mice. Importantly, administering two consecutive, non-toxic i.p. bolus doses of 25 mg/kg of WHI-P180 suppresses IgE/antigen-induced vascular hyperpermeability in a validated mouse model of passive cutaneous anaphylaxis. |
| Molecular Weight | 333.77 |
| Formula | C16H16ClN3O3 |
| Cas No. | 153437-55-9 |
| Smiles | Cl.COc1cc2ncnc(Nc3cccc(O)c3)c2cc1OC |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.